AI assistant
Sending…
Moderna, Inc. — Director's Dealing 2020
Mar 4, 2020
30610_dirs_2020-03-04_fa1279cc-a6c7-49bb-bb19-2b5d14744003.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-03-02
Reporting Person: Andres Juan (See remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-03-02 | Common Stock | M | 3001 | $12.21 | Acquired | 3001 | Direct |
| 2020-03-02 | Common Stock | S | 3001 | $30.12 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-03-02 | Stock Option (Right to Buy) | $12.21 | M | 3001 | Disposed | 2027-08-29 | Common Stock (3001) | Direct |
Footnotes
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.
More from Moderna, Inc.
Declaration of Voting Results & Voting Rights Announcements
2026
May 11
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Feb 25
Regulatory Filings
2026
Feb 23
Annual Report
2026
Feb 20
Director's Dealing
2026
Feb 13
Director's Dealing
2026
Feb 13